No Placebo-Only Group

The purpose of this study is to see whether taking indinavir (IDV) plus ritonavir (RTV) plus stavudine (d4T) plus lamivudine (3TC) 2 times each day is safe and can lower the level of HIV in the blood.

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

Anti-HIV Drug Combination for HIV

This study is evaluating whether a combination of drugs can lower the level of HIV in the blood.

I am willing to stop all HIV medications except those provided by the study.

I am 16 or older and have consent if under 18.

I have taken 3TC, abacavir, or a protease inhibitor before.

I am allergic to certain HIV medications.

I have not used any of the specified medications.

I have cancer, lung disease, severe hepatitis, or active AIDS but certain conditions like Kaposi's sarcoma might be allowed.

Indinavir

Lamivudine

Ritonavir

Stavudine

Pivotal Trial

To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy ABV: Adriamycin (doxorubicin)/bleomycin/vincristine. To evaluate the safety and tolerance of DOX-SL compared to ABV in a population of AIDS patients with severe KS.

A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

DOX-SL vs. Chemotherapy for Kaposi Sarcoma

This study is evaluating whether a new drug called Stealth liposomal doxorubicin hydrochloride (DOX-SL) is better than the standard drug called Adriamycin (doxorubicin)/bleomycin/vincristine (ABV) in

I am not currently taking any other chemotherapy drugs or Ganciclovir.

My Kaposi's sarcoma is worsening and confirmed by biopsy.

I haven't had radiation or electron beam therapy in the last 3 weeks.

I am on stable doses of medications for PCP, cryptococcal, herpes infections, and HIV.

My bone marrow function is permanently damaged due to extensive chemotherapy for a previous cancer.

I do not have an active infection while on drugs that can lower my immunity.

I haven't had anthracycline, chemotherapy, or interferon treatments in the last 4 weeks.

I do not have serious heart, liver, or kidney disease.

I am not on treatment for TB, fungal, or herpes infections that affects my bone marrow.

I am not currently using medications to boost my blood cell counts.

I am taking Foscarnet for a new CMV infection.

I experience significant numbness or weakness in my limbs.

Adriamycin

Bleomycin

DOX-SL

Vincristine

The purpose of this study is to see if it is safe to give indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC) to HIV-positive patients who have never received anti-HIV therapy. This study will look at the effectiveness of this drug combination and side effects.

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

HIV Drug Combination for HIV

This study is evaluating whether a drug combination is safe and effective for HIV-positive patients who have never received anti-HIV therapy.

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically.

PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

High-Dose Interferon Alfa for Melanoma

This study is evaluating whether interferon alfa can improve survival for people with melanoma.

My skin cancer is at Stage II with a thickness of 1.5-4.0 mm.

My lymph nodes do not show signs of cancer, either by clinical exam or biopsy.

My cancer is stage III with a tumor thicker than 4mm or has spread to one lymph node.

Interferon alfa-2b

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Specialized radiation therapy delivers a high dose of radiation directly to the tumor which may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and specialized high-dose radiation therapy in treating patients who have stage II or stage III non-small cell lung cancer that cannot be removed by surgery.

Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

Chemotherapy + Radiation for Lung Cancer

This study is evaluating whether a combination of chemotherapy and radiation therapy is more effective than chemotherapy alone in treating people with non-small cell lung cancer.

I have not had radiation therapy to my chest or neck.

My cancer has not spread through my bloodstream.

My lung cancer has not returned after surgery.

I do not have fluid in my lungs, except if it's after chest surgery.

My heart rhythm is stable without any uncontrolled irregularities.

My lung cancer has not been surgically removed and is advanced but not spread far.

I am mostly able to care for myself and carry out daily activities.

I have lost less than 5% of my weight in the last 3 months.

I do not have any heart problems that cause symptoms.

I haven't had any cancer except for skin cancer in the last 3 years.

I have not had a heart attack in the last 6 months.

Combination Chemotherapy

Specialized High-Dose Radiation Therapy

The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this study, Trizivir will be compared to Combivir plus abacavir.

Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

Trizivir for HIV

This study is evaluating whether a pill called Trizivir is safe and effective for people with HIV.

I have a stomach or intestine problem that affects how I absorb food or take pills.

I have taken or will need treatments like chemotherapy, radiation, or specific drugs for my condition.

I am on my first HIV treatment regimen, which includes Combivir and abacavir, for at least 16 weeks.

Abacavir

Zidovudine

The purpose of this study is to see if valacyclovir (Valtrex) is a safe and effective treatment for ano-genital HSV infections (herpes simplex virus infections of the anus and external genitals) in HIV-infected patients.

A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients

Valacyclovir for Genital Herpes in HIV-Infected Patients

This study is evaluating whether valacyclovir is safe and effective for treating ano-genital herpes in HIV-infected patients.

I have been on HIV treatment for at least 2 months.

I have had 4 or more genital herpes outbreaks in the past year.

I have a disease affecting my blood vessels.

I am willing to stop my anti-herpes medication for the study.

I am willing to stop interferon treatment to join the study.

My HSV infection is resistant to common antivirals.

I have open sores on my genitals or anus.

Valacyclovir

The purpose of this study is to compare the safety and effectiveness of emtricitabine and stavudine when given with didanosine plus efavirenz to HIV-infected patients.

A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Emtricitabine/Stavudine + Didanosine/Efavirenz for HIV Infection

This study is evaluating whether a combination of drugs is better than a single drug for treating HIV.

I cannot eat one or more meals a day due to ongoing symptoms.

I am currently receiving treatment for active tuberculosis.

I am not taking medications like astemizole, cisapride, or St. John's wort.

I have or had nerve damage in my hands or feet.

I have not used HIV medication for more than 2 days.

I am willing to use effective birth control during the study.

I have had certain serious infections or cancers in the past.

I cannot take medicine by mouth or have had severe diarrhea recently.

Didanosine

Efavirenz

Emtricitabine

All Individual Drugs Already Approved

Approved for 30 Other Conditions

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibodies given together with combination chemotherapy to see how well they work in treating patients with newly-diagnosed non-Hodgkin's lymphoma.

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Chemotherapy + Monoclonal Antibody Therapy for Non-Hodgkin's Lymphoma

This study is evaluating whether a combination of 2 monoclonal antibodies plus chemotherapy is more effective than a combination of 2 monoclonal antibodies plus chemotherapy in treating patients with newly diagnosed non-Hodgkin's lymphoma.

I have never received monoclonal antibody treatment for cancer.

My lymphoma has not spread to my brain or spinal cord.

I have been diagnosed with congestive heart failure.

I have been diagnosed with cardiomyopathy.

I haven't had any cancer in the last 5 years, except for certain skin cancers or cervical pre-cancer.

I have not had radiation therapy for lymphoma.

I have not had chemotherapy for lymphoma before.

My condition is graded between I and III.

I can take care of myself and am up and about more than half of my waking hours.

I have a type of lymphoma that has not been treated and is in an advanced stage.

Cyclophosphamide

Doxorubicin

Rituximab

Tositumomab

The purpose of this study is to compare virus response to GW433908/ritonavir (RTV) to viral response to nelfinavir (NFV) when used with abacavir (ABC)/lamivudine (3TC) in patients that have not taken antiretroviral (ART) drugs.

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

Antiretroviral Therapy Regimen for HIV

This study is evaluating whether a drug combination can be used to treat HIV.

You have previously participated in studies testing new treatments or medications.

I have a serious health condition like diabetes or heart disease.

I haven't had chemotherapy or radiation in the last 28 days and won't need them during the study.

I haven't taken immune-affecting or anti-HIV drugs in the last 28 days.

I do not abuse drugs or alcohol in a way that would affect my participation in the study, or I am stable on methadone.

I have had pancreatitis or hepatitis in the last 6 months.

I have received an HIV vaccine in the last 3 months.

I haven't taken certain drugs in the last 28 days and don't expect to need them during the study.

I've taken NRTI for less than 4 weeks and never taken NNRTI or PI, except possibly one dose of nevirapine during pregnancy.

I am at least 13 years old and have consent if under 18.

GW433908/Ritonavir

Nelfinavir

Drug Has Already Been Approved

The purpose of this study is to determine the effect of treatment with Trizivir (TZV) plus efavirenz (EFV) or TZV alone on viral load (level of HIV in the blood).

Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

TRIZIVIR + Efavirenz for HIV

This study is evaluating whether a combination of two drugs can reduce the amount of HIV in the blood.

I haven't had radiation, chemotherapy, or immune-affecting drugs in the last 4 weeks.

I have not had an HIV vaccine in the last 3 months nor plan to during the study.

I am committed to completing the study and taking the drugs as required.

If I am under 18, my parent or guardian has agreed to the treatment.

I have a stomach or intestine problem that affects how I absorb medicine.

I am not allergic to the study drugs or their ingredients.

I have been on anti-HIV medication for at least 2 weeks.

I have had hepatitis in the last 6 months.

I have taken medication for HIV that is not a nucleoside.

I am not taking astemizole, cisapride, midazolam, triazolam, or ergot derivatives.

Abacavir/Lamivudine/Zidovudine

The purpose of this study is to see if emtricitabine is safe in children infected with HIV and to determine the best dose.

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

Emtricitabine for HIV in Children

This study is evaluating whether emtricitabine is safe in children infected with HIV.

My child hasn't had a serious illness within the last 30 days.

I am between 3 months and 17 years old and HIV positive.

My child weighs over 5.5 pounds or was born at 38 weeks or later.

My parent or guardian has agreed in writing for me to participate.

I am a child and not pregnant or breast-feeding.

My child has nerve damage in their arms or legs.

My child had an AIDS-related illness in the last year.

My child is receiving treatment for tuberculosis.

My child has HIV and meets the specific viral load criteria.

My child cannot follow the study schedule or be available for a year.

My child struggles with eating or taking medication.

My child had severe diarrhea in the last 30 days.

This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Isotretinoin +/- Immunotherapy for Neuroblastoma

This study is evaluating whether a combination of chemotherapy, isotretinoin, dinutuximab, aldesleukin, and sargramostim is more effective than chemotherapy alone in treating patients with neuroblastoma.

My heart's pumping ability is confirmed to be normal by recent tests.

I have high-risk neuroblastoma, or it became high-risk after initial diagnosis.

I completed therapy for my cancer, including intensive treatment and a stem cell transplant.

My seizures are under control with medication and I have no severe brain-related side effects.

My parent or guardian has given written consent for me to participate.

I am eligible for a second stem cell transplant.

My latest bone marrow tests show less than 10% tumor cells before my stem cell transplant or joining this study.

I started my first chemotherapy for high-risk neuroblastoma less than 12 months ago.

I've had recent scans and tests to check my cancer's stage before joining the trial.

I've completed therapy for neuroblastoma, including intensive treatments and possibly surgery.

I am eligible for a tandem transplant and have followed specific treatment protocols within the last 12 months.

My veno-occlusive disease is stable or getting better.

My lung function tests are above 60% of what's expected, or I'm a child without breathing issues.

My neuroblastoma shows a positive response according to specific criteria before stem cell transplant.

My kidney function is within the required range for my age and gender.

I have never received GD2 antibody therapy.

I can do most activities and my doctor thinks I have at least 2 months to live.

I still have cancer after radiotherapy but haven't had a biopsy.

My neuroblastoma shows a positive response to treatment before stem cell transplant.

My kidney function is normal or near normal.

Aldesleukin

Dinutuximab

Isotretinoin

Sargramostim

Approved for 10 Other Conditions

RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Ovarian Suppression + Tamoxifen/Exemestane for Breast Cancer

This study is evaluating whether ovarian function suppression with either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer.

Miami Clinical Trials 2022

Trials at this site

Is this your site?

Is this your site?